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Structural brain changes underlying mild cognitive impairment (MCI) have been well-
researched, but most previous studies required subjective cognitive complaints (SCC)
as a diagnostic criterion, diagnosed MCI based on a single screening test or lacked
analyses in relation to neuropsychological impairment. This longitudinal voxel-based
morphometry study aimed to overcome these limitations: The relationship between
regional gray matter (GM) atrophy and behavioral performance was investigated over
the course of 3 years in individuals unaware of cognitive decline, identified as amnestic
MCI based on an extensive neuropsychological test battery. Region of interest analyses
revealed GM atrophy in the left amygdala, hippocampus, and parahippocampus in MCI
individuals compared to normally aging participants, which was specifically related to
verbal memory impairment and evident already at the first measurement point. These
findings demonstrate that GM atrophy is detectable in individuals with amnestic MCI
despite unawareness of beginning cognitive decline. Thus, individuals with GM atrophy
in regions associated with verbal memory impairment do not necessarily need to
experience SCC before meeting neuropsychological criteria for MCI. These results have
important implications for future research and diagnostic procedures of MCI.
Keywords: mild cognitive impairment, voxel-based morphometry, subjective cognitive complaints, gray matter
atrophy, amygdala, hippocampus, longitudinal
INTRODUCTION
Age-related neurodegenerative diseases such as Alzheimer’s disease (AD) impose a high social and
financial burden for society that will increase in the following decades, given predictions of a 9%
increase of people above 60% in 2050 (United Nations, Department of Economic and Social Affairs,
2013). Along with population aging, the prevalence of AD (currently 4.7%) is predicted to increase
by approximately 225% by 2050 (Prince et al., 2013).
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Memory disturbances constitute early symptoms of AD, and
with progressing impairment, other domains become affected,
including language, problem-solving, and visuospatial perception
(for a review, see Dubois et al., 2016). The neuropathological
hallmarks of AD are brain atrophy, extracellular amyloid plaques,
and neurofibrillary tangles (Kandel et al., 2013), yet its underlying
cause remains unidentified (Zetterberg and Mattsson, 2014).
Early diagnosis is in dire need for disease prevention and the
development of new treatment strategies. Detecting AD at an
early time point would enable early intervention and a timely
start of treatment, possibly preventing disease progression.
A promising endeavor to provide such early diagnosis lies
in the identification of the transitional state between normal
aging and pathological cognitive decline. Since 1997, the term
mild cognitive impairment (MCI) is used to mark the difference
between continuous levels of cognitive impairment in normally
aging controls compared to AD patients (Petersen et al., 1997).
The concept of MCI is now widely accepted and continues to
receive great attention in the literature as it represents a possible
treatment target for AD. Its predictive power is reflected in
annual conversion rates of up to 15% from MCI to AD (DeCarli,
2003) compared to conversion rates of 1–2% from normal aging
to AD (Petersen et al., 1999).
Currently, MCI is diagnosed by: (a) abnormal cognitive
function adjusted for age and education level, (b) self-reported
cognitive complaints, (c) normal activities of daily living, and
(d) absence of a dementia diagnosis (Winblad et al., 2004).
Impairment severity is commonly assessed on the basis of
general cognitive screening tests, such as the Mini-Mental State
Examination (MMSE). However, such tests have been criticized
for being not sufficiently specific regarding the subtle nature of
MCI (Nickl-Jockschat et al., 2012; Forlenza et al., 2013). Even
if specific neuropsychological tests for MCI diagnosis are used,
studies often rely on only one diagnostic test (Bondi et al.,
2014). Moreover, there is great variation in how the criteria for
aberrant cognitive function are implemented. Thus, there is no
standardized approach for diagnosing MCI, and prevalence rates
are therefore highly dependent on the classification scheme used
(Chapman et al., 2016; Clark et al., 2016). Furthermore, MCI was
originally conceptualized as a prodromal stage for AD and thus
focused on memory impairment (Petersen et al., 1999). However,
MCI has been revealed to be a much broader construct affecting
several cognitive domains (Winblad et al., 2004). Thus, extensive
neuropsychological testing is required to identify early-stage
MCI.
Critically, doubts have arisen regarding subjective cognitive
complaints (SCC), which are currently implemented in the
diagnosis of MCI. While these may be a marker of MCI (Clark
et al., 2016), including SCC may lead to false omission of
possible MCI candidates who are misdiagnosed as healthily
aging individuals because they are not yet aware of beginning
cognitive impairment (Edmonds et al., 2014). Such a lack of
awareness has indeed been identified by several studies (e.g.,
Purser et al., 2006; Lenehan et al., 2012; Fragkiadaki et al., 2016;
for a review, see Roberts et al., 2009), and the inclusion of SCC
resulted in increased rates of false negative and false positive
diagnoses (Lenehan et al., 2012). Moreover, subjective complaints
are strongly related to individual differences in depression and
neuroticism, casting further doubt on their reliability as a
diagnostic marker of MCI (Reid and MacLullich, 2006). Taken
together, the drawbacks of including SCC in the diagnosis of MCI
seem to outweigh its benefits. Thus, the present study took a novel
approach by investigating MCI in elderly individuals unaware of
any cognitive impairment.
In addition to more thorough neuropsychological testing,
the need for neuroanatomical biomarkers of MCI has been
recognized (Ruan et al., 2016). For AD, the most widely studied
biomarkers are: decreased cerebrospinal fluid amyloid beta (CSF
Aβ), increased CSF tau, decreased fluorodeoxyglucose uptake
on positron-emission tomography (FDG-PET), PET amyloid
imaging, and structural MRI measures of cerebral atrophy.
Importantly, strong evidence suggests that MRI, FDG-PET, and
CSF tau biomarkers are already abnormal in the MCI phase of
AD (Ewers et al., 2007; Sluimer et al., 2008; Shaw et al., 2009), and
while both CSF tau and MRI are predictive of conversion from
MCI to AD, the predictive power of structural MRI is greater.
Moreover, cognitive measures correlate strongly with structural
MRI, but not with CSF tau in patients with MCI (Vemuri et al.,
2009). Structural MRI studies using longitudinal voxel-based
morphometry (VBM) identified the medial temporal lobe (MTL)
as a core region for progression of MCI to AD (Ferreira et al.,
2011; Nickl-Jockschat et al., 2012; Yang et al., 2012). This is not
surprising given that the MTL contains essential structures for
memory consolidation (Kandel et al., 2013). The identification
of progressing MCI patients can be made apparent already
4 years prior to conversion to AD on the basis of hippocampal
atrophy patterns (Adaszewski et al., 2013). Comparing rates of
hippocampal atrophy between healthy controls, MCI individuals
and AD patients, annual atrophy rates of 1.9–2.8% were observed
for the controls, 2.6–3.7% for MCI individuals, and 3.5% for
AD patients (Jack et al., 2000). Moreover, meta-analyses indicate
that a consistent atrophy pattern underlies MCI, comprising
the amygdala, hippocampus, precuneus, and posterior cingulate
gyrus (Nickl-Jockschat et al., 2012; Yang et al., 2012).
Although gray matter (GM) changes accompanying MCI have
been well-researched, most of the previous studies identified MCI
on the basis of general cognitive screening tests such as the
MMSE, which may be insufficient to capture the subtle nature of
MCI and presumably identifies MCI at a rather late stage, missing
the beginning of cognitive decline. Even if the MMSE was not
used for MCI diagnosis, previous VBM studies correlated GM
atrophy with cognitive decline based on the MMSE and thus lack
analyses in relation to specific behavioral impairment (e.g., Jack
et al., 2000; Whitwell et al., 2007; Sluimer et al., 2008; Weiner
et al., 2013).
The present study aimed to overcome these limitations by
taking a novel, more sensitive approach: Elderly volunteers
(minimum age: 50 years) from a community sample were
included who had no subjective complaints, i.e., were not
aware of potential cognitive impairment. MCI was then
identified on the basis of a thorough neuropsychological test
battery assessing memory, intelligence, executive functions,
psychomotor speed, visuo-construction and visuo-spatial skills,
attention, and language. To our knowledge, this is the
Frontiers in Aging Neuroscience | www.frontiersin.org 2 February 2017 | Volume 9 | Article 34
fnagi-09-00034 February 22, 2017 Time: 10:31 # 3
Goerlich et al. Neuroanatomical and Neuropsychological Markers of Amnestic MCI
first VBM study investigating the longitudinal trajectory
of morphological changes underlying early-stage MCI in
individuals still unaware of beginning cognitive impairment. We
predicted more pronounced region of interest (ROI) GM atrophy
in individuals classified as MCI compared to HCs even without
subjective awareness of cognitive deficits, and hypothesized faster
atrophy rates in the MCI compared to the HC group. Moreover,
we hypothesized ROI GM atrophy to be related to specific
behavioral impairment in the MCI group only.
MATERIALS AND METHODS
Participants
Participants for the Helmholtz Alliance for Mental Health in
an Aging Society (HelMA) study (Drexler et al., 2013; Chechko
et al., 2014; Ellendt et al., 2016) were recruited through visitations
to social facilities for elderly people (charity organizations and
citizen centers) and advertisements in local newspapers. From
81 volunteers initially participating in the first measurement
time point (T1), 43 participants (27 women, aged 50–83 years)
eventually completed all three measurement time points (T1,
T2, and T3) with a mean follow-up interval of 1.12 years, SD
0.38 years. Reasons for dropping out varied from refusing to
further participate for time reasons or a lack of interest (13
participants), moving to another city (four participants), newly
acquired MR contraindications following surgery during the
course of the study (six participants), to illness (11 participants)
and death (four participants).
Participants were included if they were 50 years or older,
had sufficient German language and adequate visual performance
abilities. Exclusion criteria comprised a diagnosis of dementia,
neurological or psychiatric disorders according to DSM-IV
axis I as assessed by the German version of Structured
Clinical Interview (SKID; Wittchen et al., 1997), physical
disease that could interfere with cognitive performance, lifetime
or current drug addiction, seriously reduced vision, inability
to follow the protocol, and medication use with possible
cognitive side effects. The study was approved by the ethics
committee of the medical faculty, RWTH Aachen University. All
participants gave written informed consent and were paid for
participation.
Neuropsychological Data Analysis
In addition to several dementia screening tests applied with
the objective of eliminating dementia rather than diagnosing
MCI, all participants underwent an extensive neuropsychological
test battery evaluating memory, intelligence, executive functions,
psychomotor speed, visuo-construction and visuo-spatial skills,
attention, and language at each time point. Table 1 provides an
overview of all neuropsychological tests used for MCI assessment
and diagnosis (for further details, see Drexler et al., 2013; Ellendt
et al., 2016). The testing procedure was accomplished by trained
psychologists. To counteract learning effects, tests were presented
in counterbalanced order. Sessions took place in the mornings
and lasted approximately 3 h. Short breaks were offered and if
necessary, a second appointment was arranged.
TABLE 1 | Neuropsychological test battery used for the assessment and
diagnosis of mild cognitive impairment (MCI).
Domain Test
Memory Benton Visual Retention Test (BRVT) Wechsler Memory
Scale – digit span (WMS-R) California Verbal Learning
Test, German version (VLMT)
Intelligence Premorbid intelligence; Multiple-choice word test,
German version (MWT-B)
Executive functions Cognitive flexibility, divided attention, psychomotor speed:
Trail-Making-Test A and B (TMT A/B) Planning and
problem-solving: Tower of London (TL-D) Lexical and
semantic fluency: Regensburger Wortflüssigkeitstest
(RWT)
Dementia screening Mini-Mental-State-Examination, German version (MMSE)
Syndrom Kurz Test (SKT) Test zur Früherkennung von
Demenzen (TFDD) Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD-PLUS) including language,
object naming abilities (Boston Naming Test), verbal
learning, visuospatial functions, delayed recall, memory
consolidation, recognition, executive functions
The classification criteria for MCI were based on those
described by Winblad et al. (2004). That is, (1) greater memory
impairment than expected for age, (2) preserved activities of
the daily living, and (3) absence of dementia. The criterion of
memory impairment greater than expected for age was identified
by an impaired score of at least 1.5 standard deviations (SD)
below the mean according to normative datasets in at least one
test assessing memory functioning (i.e., VLMT, Benton, WMS,
memory assessing subtests of the CERAD-Plus battery). If the
neuropsychological test comprised multiple subtests (as in VLMT
and CERAD), at least two subtests had to indicate impairment,
i.e., 1.5 SD below normative data, which is considered a
conservative method for identifying MCI (Jak et al., 2009). The
decision to classify subjects solely on their performance in tests
regarding memory functioning can be accounted on the fact
that amnestic MCI patients show a higher prevalence to develop
AD compared to non-amnestic MCI patients, who have an
increased risk of developing other types of dementia (Petersen
and Morris, 2005). Note that impairment in cognitive domains
other than memory was not observed in this sample. Thus, all
MCI participants identified here can be classified as belonging
to the single-domain amnestic MCI subtype. Correspondingly,
the present results are of relevance specifically to amnestic
MCI.
The original classification criteria proposed by Winblad et al.
(2004) also include SCC but because the requirement of SCCs
could lead to omitting subjects which would otherwise be
classified as MCI (Edmonds et al., 2014), this criterion was not
applied. In fact, all participants reported not to have experienced
any difficulties regarding memory or any other cognitive domain
beyond expected for their respective age. Thus, none of the
participants were aware of any cognitive impairment.
The neuropsychological data were analyzed in SPSS 20 by
means of multivariate analyses of covariance (MANCOVA)
comparing performance between the MCI group and the HC
group at each time point, corrected for age, gender, and
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education. The initial significance threshold was p < 0.05, and
all results were Bonferroni corrected for multiple comparisons.
VBM Data Analysis
T1 anatomical images (TE: 3.03; TR: 2300 ms;
FOV= 256 mm× 256 mm; number of sagittal slices= 176; voxel
size: 1 mm× 1 mm× 1 mm) from the 43 study participants were
acquired on a 3 Tesla Siemens R© Trio MR scanner. Differences in
GM volume between the MCI and HC group were assessed using
longitudinal VBM (Ashburner and Friston, 2000; Ashburner
and Ridgway, 2013) implemented in SPM12 (Wellcome Trust
Centre for Neuroimaging, University College London, London,
UK). The following preprocessing steps were applied: First,
serial longitudinal registration, which produces one midpoint
file and Jacobian determinants for each subject at each of the
three time points. Next, each subject’s midpoint average was
segmented into GM, white matter (WM), and CSF. Then, GM
images were computed for each subject at each time point
using the respective Jacobian determinants. These images were
spatially normalized by creating a customized group-specific
template using the DARTEL approach and warping each of
the individual GM segmentations onto this template. The
warped GM segmentations were modulated to reflect the
volume and smoothed using a Gaussian kernel of 8 mm at full
width at half-maximum (FWHM). Data quality was ensured
by visually checking each T1 image for abnormalities before
preprocessing, checking volume orientation before smoothing
during preprocessing, and by means of a sample homogeneity
check after preprocessing, revealing no outliers.
Region of interest analyses were performed on GM volumes
of eight anatomically defined a priori ROIs based on MCI
meta-analyses (Nickl-Jockschat et al., 2012; Weiner et al., 2013):
Left and right amygdala, hippocampus, parahippocampus, and
precuneus. Anatomical ROIs for these regions were created using
the automatic anatomic labeling (AAL) atlas templates (Tzourio-
Mazoyer et al., 2002) provided by the WFU Pickatlas toolbox
(Wake Forest School of Medicine, Winston Salem, NC, USA).
Mean parameter estimates from these ROIs were extracted using
MarsBaR1 and analyzed by means of a Linear Mixed Model
(LMM) Analysis in SAS 9.2. The factor group (MCI versus HC)
was included in the LMM as a between-subjects fixed effect,
and the model controlled for age, gender, education, and mean
total intracranial volume (TIV, i.e., GM + WM + CSF). An
unstructured covariance matrix was used, which was estimated
by means of the null model estimation method.
Relationships between mean neuropsychological performance
and mean GM volumes of the eight ROIs across the whole sample
and within the HC and the MCI group were examined by means
of partial correlations controlling for age, gender, education, and
TIV. To this end, the residuals of each neuropsychological test
as well as the residuals of the GM volumes of each ROI at
each measurement point were calculated, controlling for age,
gender, education, and TIV, and partial correlations were then
performed between the neuropsychological test residuals and
the ROI GM volume residuals. The Holm–Bonferroni correction
1http://marsbar.sourceforge.net/
was applied to control for multiple comparisons, resulting in
an initial significance threshold of p < 0.006 (p = 0.05/n = 8
ROIs). Moreover, whole-brain analyses comparing GM volumes
between the MCI and HC group at each time point were
conducted at an uncorrected threshold p< 0.001.
RESULTS
Neuropsychological Performance
Based on the neuropsychological test battery, 16 participants
were classified as MCI (6 male, mean age 66.13, SD 8.46 years,
mean years of education 9.43, SD 1.59), and 27 participants were
classified as HC (10 male, mean age 66.15, SD 6.15 years, mean
years of education 10.5, SD 1.88). Groups did not differ in age
(p > 0.05), but the HC group had more years of education
(p < 0.05). The results on the neuropsychological tests for the
HC and the MCI group are presented in Table 2, revealing
significantly worse performance of the MCI group compared to
the HC group on the total immediate recall and delayed recall
subtests of the VLMT and the CERAD. At a lower significance
threshold (p < 0.05 uncorrected), worse performance was
additionally observed in the Benton test (correct drawings and
number of mistakes) and the WMS-R subtests digit span forward
and backward. The MMSE could not distinguish between the
MCI and the HC group, as opposed to the TFDD, which indicated
lower performance in MCI compared to HC participants (see
Table 2). Note that none of the study participants converted to
dementia during the course of the investigation.
ROI GM Volumes
The LMM analyses on each ROI demonstrated a linear decrease
in all ROI GM volumes in both groups over the course of
the 3 years of observation. A group analysis between the MCI
and HC group revealed significantly lower GM volume in
the left amygdala, left hippocampus, and left parahippocampus
in MCI participants compared to HCs at all three time
points (see Table 3). Thus, MCI participants had significantly
lower GM volume than controls in these areas already at the
first time point, which then continued to decrease over the
course of the following 2 years (effect of time in these ROIs:
p < 0.001; see Figure 1A). However, there was no significant
interaction between group and time point (p > 0.05), suggesting
that atrophy rates were comparable between groups. Whole-
brain analyses additionally indicated smaller left amygdala
and left hippocampal volumes in the MCI compared to the
HC group at each time point (see Figure 1B). No further
activation outside of the ROIs was observed at p < 0.001. For
visualization, Figure 2 shows the decrease of ROI GM volumes
across the age range of 50–83 years at T1 in MCI and HC
participants.
Associations between ROI GM Volumes
and Neuropsychological Performance
Relating mean neuropsychological performance with mean ROI
GM volumes across all 3 years within the whole sample showed
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TABLE 2 | Neuropsychological test results for the MCI group compared to the HC group.
MCI HC MCI vs. HC
T1−3Mean ± SEM T1−3 Mean ± SEM T1−3Mean
T1 T2 T3 T1 T2 T3 p-value
VLMT
Total immediate recall 45.56 ± 7.05 54.85 ± 5.75 0.0002∗∗
43.69 45.75 47.25 52.89 54.30 57.37
Delayed recall 8.83 ± 2.06 11.82 ± 1.99 0.0001∗∗
8.56 8.63 9.31 11.15 11.67 12.63
Lost words 2.98 ± 1.79 1.59 ± 1.33 0.09
2.75 3.06 3.13 1.85 1.63 1.30
Correct recognition 13.31 ± 0.92 14.37 ± 0.7 0.01∗
13.5 12.81 13.63 14.11 14.48 14.52
Recognition residuals 10.63 ± 2.15 12.96 ± 1.63 0.01∗
11.5 9.5 10.88 12.85 12.70 13.33
WMS-R
Digit span forward 6.94 ± 1.64 7.89 ± 1.17 0.051
6.94 7.38 6.5 8.26 7.63 7.78
Digit span backward 5.69 ± 1.39 6.72 ± 1.13 0.09
5.63 5.88 5.56 6.67 6.48 7.00
Benton
Correct drawings 6.02 ± 1.59 7.21 ± 1.21 0.049∗
5.19 6.31 6.56 6.52 7.56 7.56
Number of mistakes 6.27 ± 2.97 3.76 ± 1.96 0.15
7.25 6.19 5.38 4.78 3.30 3.22
CERAD
Total immediate recall 20.23 ± 3.13 23.41 ± 2.14 0.001∗∗
19.94 19.06 21.69 23.19 22.96 24.07
Delayed recall 6.48 ± 1.36 8.41 ± 1.08 0.00003∗∗
6.31 5.81 7.31 8.41 8.04 8.78
Percent recognition 96.88 ± 3.49 99.38 ± 1.24 0.007∗
97.19 96.88 96.56 98.89 99.63 99.63
Intrusions 0.46 ± 0.64 0.31 ± 0.43 0.75
0.56 0.25 0.56 0.41 0.19 0.37
Recall drawings 8.73 ± 1.89 10.59 ± 1.69 0.05
7.88 8.25 10.06 9.85 10.48 11.44
General screening tests
MMSE 28.91 ± 0.65 29.27 ± 0.59 0.32
28.81 28.88 29.06 29.22 29.33 29.26
SKT 2.17 ± 2.11 1.09 ± 1.19 0.074
2.0 2.06 2.44 1.33 0.74 1.22
TFDD 42.63 ± 2.12 45.84 ± 1.76 0.0001∗∗
42.44 42.44 43.00 45.48 45.22 46.82
∗∗p < 0.006 Bonferroni-corrected, ∗p < 0.05 uncorrected.
that the association between CERAD total immediate recall
performance and larger GM volume in the left amygdala (partial
r = 0.49, p < 0.002), left hippocampus (partial r = 0.51,
p< 0.001), and left parahippocampus (partial r= 0.52, p< 0.001)
remained, indicating a robust relationship between CERAD
total immediate recall performance and GM volume in these
regions. In addition, WMS-R digit span forward performance was
linked to larger left parahippocampal volume (partial r = 0.44,
p< 0.006).
Partial correlations between neuropsychological performance
and ROI GM volumes within each group revealed that
the abovementioned associations were solely driven by the
MCI group as there were no significant correlations between
neuropsychological performance and ROI GM volume in the HC
group (all p > 0.05). In the MCI group, CERAD total immediate
recall performance was highly correlated with GM volume in the
left amygdala (partial r = 0.83, p < 0.001), left hippocampus
(partial r = 0.72, p < 0.006), and left parahippocampus (partial
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TABLE 3 | Results of the linear mixed model (LMM) analysis comparing mean region of interest (ROI) volumes between the MCI and HC group.
ROI MCI HC MCI vs. HC
T1−3 Mean ± SEM T1−3 Mean ± SEM T1−3 Mean
T1 T2 T3 T1 T2 T3 p-value
Amygdala Left 0.557 ± 0.01 0.597 ± 0.01 0.006∗∗
0.559 0.557 0.553 0.600 0.597 0.594
Right 0.575 ± 0.01 0.595 ± 0.01 0.454
0.578 0.575 0.572 0.598 0.595 0.592
Hippocampus Left 0.357 ± 0.01 0.379 ± 0.01 0.012∗
0.357 0.356 0.355 0.380 0.380 0.379
Right 0.345 ± 0.01 0.359 ± 0.01 0.217
0.346 0.345 0.344 0.359 0.359 0.358
Parahippocampus Left 0.471 ± 0.01 0.493 ± 0.01 0.048∗
0.473 0.472 0.369 0.495 0.493 0.491
Right 0.546 ± 0.01 0.566 ± 0.01 0.342
0.548 0.546 0.543 0.568 0.566 0.564
Precuneus Left 0.303 ± 0.01 0.307 ± 0.01 0.982
0.304 0.303 0.302 0.307 0.306 0.305
Right 0.324 ± 0.01 0.328 ± 0.01 0.859
0.325 0.325 0.323 0.329 0.328 0.327
∗∗p < 0.006 Bonferroni-corrected, ∗p < 0.05 uncorrected.
r = 0.80, p < 0.002), implying a robust relationship between
verbal memory impairment and GM volume reduction in these
regions. MMSE scores showed no correlation with ROI GM
volumes (all p > 0.05). Figure 3 visualizes the relationship
between mean CERAD total immediate recall performance and
mean GM volumes of the left amygdala, hippocampus, and
parahippocampus in the MCI and HC group across the three time
points.
To find out to what extent GM atrophy in these ROIs
significantly predicted verbal memory impairment in MCI
participants already at the first measurement point, a stepwise
linear regression was performed with the residuals (i.e.,
controlling for age, gender, education, and TIV) of CERAD total
immediate recall performance at T1 as dependent variable and
the residuals of GM volumes of the left amygdala, hippocampus,
and parahippocampus at T1 as predictors. From this analysis,
a significant model emerged [F(1,24) = 5.79, p < 0.05,
R2 = 0.29], revealing that GM atrophy specifically in the left
parahippocampus accounted for 29% of the variance in CERAD
total immediate recall performance (β= 0.54, p< 0.05). Thus, left
parahippocampal atrophy significantly predicted verbal memory
impairment in the MCI group already at the first measurement
point.
DISCUSSION
The aim of this longitudinal imaging study was to identify the
relationship between neuropsychological and neuroanatomical
changes associated with early stages of MCI identified by
means of a thorough neuropsychological test battery in
individuals unaware of cognitive impairment. Although several
previous studies investigated the longitudinal trajectory of
neuroanatomical alterations underlying MCI, these studies
diagnosed MCI on the basis of a single general screening
tests, lacked an analysis of these changes in relation to
neuropsychological performance (e.g., Besson et al., 2015;
Callahan et al., 2015; Dugger et al., 2015; Fellhauer et al., 2015;
Granziera et al., 2015), or included subjective complaints as a
diagnostic criterion. The present study aimed to overcome these
limitations. Individuals classified as MCI who were unaware
of beginning cognitive impairment exhibited verbal memory
deficits (indicative of amnestic MCI) and GM atrophy in the
left amygdala, hippocampus, and parahippocampus, compared
to controls. Atrophy rates were comparable between groups,
in contrast to our hypothesis of faster atrophy rates in MCI
individuals than in controls. In line with our prediction of
a specific relationship between GM atrophy and behavioral
impairment in MCI individuals only, GM atrophy in the
MCI group, but not the control group, was highly correlated
with impaired verbal memory (CERAD total immediate recall).
Moreover, GM atrophy in the left parahippocampus significantly
predicted verbal memory impairment in MCI individuals already
at T1, even without subjective awareness of cognitive impairment.
This confirms our prediction of GM atrophy being evident in
MCI individuals before they become aware of cognitive decline.
Lower GM volumes in the left amygdala, hippocampus,
and parahippocampus are in accordance with previous studies
reporting GM atrophy in the left MTL in MCI patients compared
to controls (Ferreira et al., 2011; Nickl-Jockschat et al., 2012;
Weiner et al., 2013; Csukly et al., 2016). Here, GM volume
reduction in these regions was significantly linked to impaired
total immediate recall performance (CERAD) in the MCI group,
suggesting that GM atrophy in the MTL is specifically associated
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FIGURE 1 | (A) Decline of region of interest (ROI) gray matter (GM) volume in the HC and mild cognitive impairment (MCI) group. (B) Whole-brain analysis: GM
volume reduction in the amygdala and hippocampus (MCI > HC).
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FIGURE 2 | Region of interest GM volume decrease across age in MCI and HC participants at T1.
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FIGURE 3 | Partial correlations controlling for age, gender, education, and TIV between CERAD total immediate recall performance and ROI GM
volume in the MCI and HC group across 3 years (Holm–Bonferroni corrected p < 0.006). (A) Left amygdala, (B) Left hippocampus, (C) Left
parahippocampus.
with verbal memory impairment. This finding complements
previous observations that cerebral atrophy correlates with
measures of general cognition in MCI (Jack et al., 2010). Atrophy
rates did not significantly differ between MCI participants and
controls, although this might be expected with progressing MCI
(e.g., Trivedi et al., 2006; for a review, see Chetelat and Baron,
2003). However, this absence of differences in atrophy rates may
be explained by the restricted time frame of the present study,
comprising 3 years, which was probably not long enough to
capture significant differences in atrophy rates. Moreover, none
of the study participants converted to dementia during the course
of the investigation, indicating that indeed early-stage MCI was
captured here, thus further explaining the absence of group
differences in GM atrophy rates. This could also explain why no
GM atrophy in the precuneus was identified here, suggesting that
atrophy in this region may occur at later stages of MCI. Note
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that MCI participants exhibited lower GM volumes compared
to controls already at the first time point. This suggests that GM
atrophy in the MCI group had already begun prior to enrolment
in the study, warranting the inclusion of younger participants
(<50 years) in future studies to be able to identify the point of
divergence in medial temporal GM atrophy between MCI and
normal aging.
According to the model of dynamic biomarkers of AD
proposed by Jack et al. (2010), structural MRI is the last
biomarker in the staging of the disease to become abnormal,
preceded by Aβ-plaque biomarkers that are dynamic in early
stages before the appearance of clinical symptoms, and by
biomarkers of neurodegeneration that occur at later stages and
correlate with symptom severity. MRI, FDG-PET, and CSF tau
biomarkers are already abnormal in the MCI phase preceding
AD. Findings of specific relationships between GM atrophy and
neuropsychological impairment as observed in this study may be
used in the future to increase prediction accuracy for conversion
from MCI to AD.
The MMSE, a general cognitive screening test that has been
commonly used to assess MCI in previous research did not show
any correlations with GM volumes in the present MCI group
and could not distinguish between the MCI and HC group:
Both groups had an average score of 29 on the MMSE and
MMSE scores remained intact over the course of the 3 years,
with none of the participants having less than 27 points on the
MMSE at any time point. Thus, the present MCI sample would
not have been identified as such based on the results of this
general screening test, despite evident cognitive impairment as
demonstrated by significantly worse performance on the VLMT
and CERAD (and tendencies toward impairment in the Benton
and WMS-R). This is in line with previous findings showing that
despite good sensitivity and specificity for diagnosing dementia,
the commonly used cutoff scores of the MMSE do not show
good accuracy for discrimination of MCI, misidentifying most of
these subjects as having normal cognitive function (Kaufer et al.,
2008). Since the MMSE is widely used in the MCI literature –
and considering that individuals are classified as MCI with
scores ranging from 23.1 to 28.7 (Nickl-Jockschat et al., 2012) –
this not only entails the risk to include already more severely
impaired individuals in MCI studies, but also causes problems
for the comparison and evaluation of the results due to high
variability in MCI diagnosis. Future studies should thus avoid
relying on the MMSE alone and instead use a broader, more
sensitive neuropsychological test battery to diagnose MCI and
assess its severity. According to the present results, the total
immediate and delayed recall scales of the VLMT and the CERAD
seem especially sensitive to identifying early stage MCI in the
absence of subjective awareness of cognitive decline. In contrast
to the MMSE, the TFDD, a screening test aiming to detect early
signs of dementia while differentiating cognitive problems due
to depression, could distinguish between the MCI and the HC
group in this study, although no between group differences on
depression were detected. Thus, it may be worthwhile using the
TFDD as an additional screening tool in future studies.
Importantly, SCCs are currently a diagnostic criterion
for MCI. None of the individuals classified as MCI in
this study were aware of any cognitive impairment (i.e.,
had no subjective complaints). Yet, the MCI group showed
significantly worse performance on more than one test of the
neuropsychological test battery. Confirming previous findings
(Edmonds et al., 2014), this supports the idea to not include
SCC as a diagnostic criterion for MCI in future studies in
order to identify GM atrophy underlying early-stage MCI
even without subjective awareness of beginning cognitive
impairment.
Limitations
The sample size of the present study was small due to a drop-
out rate of almost 50%, resulting in only 43 participants (16 MCI)
who completed all three measurement time points. High drop-
out rates are an inherent risk in longitudinal studies, particularly
those including elderly individuals. Future studies should thus
aim to include more as well as younger (<50 years) participants in
order to pinpoint at what age structural brain changes in relation
to beginning cognitive impairment become evident and divergent
from normal aging.
CONCLUSION
The present findings indicate that GM atrophy in the left
MTL underlying MCI is specifically associated with verbal
memory impairment. This underlines the importance of
combining neuroanatomical markers of MCI with specific
neuropsychological tests as it implies that age-related GM
atrophy is only predictive of MCI if accompanied by specific
cognitive deficits. Moreover, our findings show that reductions
in GM volume are evident even if individuals are not yet
aware of cognitive impairment, demonstrating that individuals
with neuroanatomical evidence of atrophy in regions associated
with verbal memory impairments do not necessarily need
to experience subjective cognitive concerns before meeting
neuropsychological criteria for MCI. Further, general cognitive
screening test such as the MMSE may not be sensitive enough
to identify early-stage MCI. These findings have important
clinical implications as they highlight the need to discard
SCCs from MCI diagnosis. Moreover, it would be useful to
apply comprehensive neuropsychological batteries, possibly by
means of computerized cognitive assessments rather than relying
on a single cognitive screening test to identify MCI. Lastly,
establishing regular neuropsychological testing for MCI already
in individuals below the age of 50 years will help identify MCI
at early stages, enabling early intervention and a timely start of
treatment.
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